Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years.
Articles on Antibody therapy
Displaying all articles
This guidance replaces previous conditional recommendations for the use of these drugs and is based on emerging evidence that they’re not likely to work against omicron.
The molecule C1q has both protective and detrimental effects after traumatic brain injury. Blocking it after injury in mice restored normal brain rhythms during sleep and prevented epileptic spikes.
Top contributors
-
Associate Professor in Clinical Immunology, University of Birmingham, University of Birmingham
-
Associate Investigator at Gladstone Institutes and Associate Professor of Neurology, University of California, San Francisco
-
University of California, San Francisco
-
Associate Professor in Viral Immunology, University of Birmingham
-
Professor and Head of the School of Life Sciences, Anglia Ruskin University